無料プレビュー

Natera, Inc. (NTRA) · NASDAQ Global Select

プロフィール

Natera is a diagnostics company applying proprietary cell-free DNA and bioinformatics technology to oncology, women's health, and organ health. It commercializes personalized blood-based tests for molecular residual disease detection, prenatal screening, carrier screening, and transplant rejection assessment. The company operates through direct sales in the U.S. and partnerships with over 100 international laboratory distributors, supported by CLIA-certified and CAP-accredited laboratories and a cloud-based software platform.

主要指標

株価: $390.79 (-1.21%)
時価総額: 560億ドル
PER（今期予想）: -276.6
PBR: 30.7
配当利回り: —
52週レンジ: $167.99 – $437.41
業種: Healthcare / Medical - Diagnostics & Research
上場: NASDAQ Global Select
構成銘柄: —

比較会社: TMO Thermo Fisher Scientific Inc.、DHR Danaher Corporation、A Agilent Technologies, Inc.、IQV IQVIA Holdings Inc.、WAT Waters Corporation、IDXX IDEXX Laboratories, Inc.、ILMN Illumina, Inc.、MTD Mettler-Toledo International Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-09